The o2h Therapeutics and AI Fund, an early stage S/EIS fund investing in biotechnology therapeutics and related AI opportunities, has invested in Pencil Biosciences, a novel gene modulation biotech company based at Alderley Park, Cheshire.

Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases.